Antipsychotics

In a study of 597 outpatients who were perceived as likely nonadherers to oral antipsychotic interventions, Spanish researchers found that relapse was lower in...

It is very common for psychiatric patients, especially those diagnosed with schizophrenia, to be prescribed two or more psychiatric medications at once, and this...

A study published today in the American Medical Association's journal JAMA Psychiatry reports that patients whose antipsychotic treatment was reduced or discontinued (DR) experienced a recovery...

A new study finds adverse long-term consequences associated with the increased use of antipsychotics in first-episode psychosis.

Research published in the Journal of Clinical Psychiatry shows that of all 901 patients diagnosed with schizophrenia from July 2009 to June 2010 at a...

Cross-sectional analysis by the University of Maryland and Johns Hopkins University of 456,315 youths enrolled in Medicaid between 1997 and 2006 finds that the...

In a featured article for Psychiatric Services, psychiatrists from Dartmouth raise the alarm on the increasing numbers of children prescribed dangerous antipsychotic drugs. Despite the fact that data on the safety of long-term use of these drugs in this vulnerable population “do not exist,” the rate of children and adolescents being prescribed antipsychotic drugs have continued to increase over the past fifteen years.

The US FDA has issued a new warning for the atypical antipsychotic Olanzapine, also known by the brand names Zyprexa and Symbyax. The agency...

Clinicians are following best practice guidelines only half of the time when giving antipsychotic medications to children, and following FDA-approved indications only one-fourth of the time.

Research from Germany finds that people with schizophrenia or schizoaffective diagnoses given multiple medications - an antipsychotic plus a benzodiazepine or more than one...

A new study finds that adding an antipsychotic to existing antidepressant treatment is associated with a 45% increased risk of early death.

An Austrian study of the baseline prevalence of metabolic abnormalities and changes following treatment with five commonly-used antipsychotic drugs (haloperidol, amisulpride, olanzapine, quetiapine or...

A 5-year study funded by the National Institute of Mental Health and conducted by U.C. San Diego School of Medicine, Stanford University and the...

A study published online today (May 26, 2012) in Current Psychiatry Reports recommends Zyprexa as "elusive" pharmacologic solution to anorexia nervosa. On the basis...

Members of the U.S. Food and Drug Administration’s Psychiatry Products division go on the defensive in a new article, responding to concerns about the agency’s approval of digital aripiprazole.

Evidence-Based Mental Health reviews studies (from 1987 to 2011) of antipsychotics in people under 24 years old, finding weak evidence on comparative effectiveness of antipsychotics or...

Antipsychotics are being prescribed to people who may have challenging behaviors but no mental disorder, according to new research published in this month’s issue of BMJ. “Excessive use of psychotropic drugs has individual and systemic implications,” the researchers write. “Antipsychotics, in particular, are associated with several adverse side effects that can impair quality of life and lead to deleterious health outcomes.”

Common psychotropic medications may be contributing to the higher rates of physical illnesses and mortality in people diagnosed with mental illnesses.

A new article in Lancet Psychiatry debunks past studies claiming that those on low doses of antipsychotics are more likely to relapse.

New research published in the August issue of Psychiatric Annals evaluates the results of randomized control trials on the use of various psychotropic drugs for patients diagnosed with borderline personality disorder (BPD). Despite the “American Psychiatric Association’s practice guidelines endorsement of SSRIs as first-line therapies for BPD,” the results of the meta-analysis reveal that pharmacotherapy in BPD is “not supported by the current literature,” and “should be avoided whenever possible.”

Researchers in the U.S. and India reviewed the pharmacological treatment of schizophrenia since its introduction 50 years ago, trying to understand why it "remains...

A paper by Joanna Moncrieff and Laura Allison in the journal History of Psychiatry reviews "the theory and practice of emergency sedation for behavioural...

More than half of the prescriptions for antipsychotic drugs in the UK are being issued "off-label" to treat conditions other than those for which the drugs are approved, according to a large study published in the British Medical Journal Open. Researchers also found significantly higher levels of prescribing of the medications to poorer people.

The FDA recently approved lumateperone for schizophrenia. A review of the clinical trials reveals a testing process that is fatally flawed, and a new drug coming to market that doesn't provide a clinically meaningful benefit.

A new analysis of antipsychotic treatment of schizophrenia (published in Schizophrenia Bulletin) has found that two-thirds of patients treated this way do not experience symptom remission.